Discovering The Potential Applications of IGHG4 as A Drug and Biomarker

Target Name: IGHG4

NCBI ID: G3503

IGHG4

Other Name(s): immunoglobulin heavy constant gamma 4 (G4m marker) | Immunoglobulin heavy constant gamma 4 (G4m marker)

Discovering The Potential Applications of IGHG4 as A Drug and Biomarker

IGHG4, also known as immunoglobulin heavy constant gamma 4 (G4m marker), is a type of protein that is expressed in the human body and is found in various tissues, including the skin, hair, and nails. It is a member of the Ig family of antibodies, which are a type of immune protein that helps to protect the body against infection and disease.

IGHG4 is a type of constant gene, which means that it is always expressed in the body and its level remains constant throughout a person's life. It is also a G protein-coupled receptor (GPCR), which means that it interacts with a protein called GPCR-伪, which is found on the surface of certain cells in the body.

IGHG4 has been identified as a potential drug target and biomarker for various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases.

One of the main reasons for the potential drug target status of IGHG4 is its role in the immune system. IGHG4 is a key component of the immune system, as it helps to protect the body against infection and disease. It is also involved in the regulation of cell growth and differentiation, which is important for the development and maintenance of tissues in the body.

In addition to its role in the immune system, IGHG4 has also been shown to be involved in various other processes in the body, including cell signaling, angiogenesis, and neurodegenerative diseases.

IGHG4 has also been identified as a potential biomarker for several diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. For example, studies have shown that IGHG4 levels are often elevated in individuals with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, and that they may be a useful biomarker for monitoring the effectiveness of certain treatments.

In addition, IGHG4 has also been shown to be elevated in individuals with certain types of cancer, such as breast cancer and melanoma. This suggests that IGHG4 may be a useful biomarker for monitoring the effectiveness of cancer treatments.

Another potential application of IGHG4 as a biomarker is its role in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that IGHG4 levels are often elevated in individuals with these conditions, and that they may be a useful biomarker for monitoring the effectiveness of certain treatments.

Overall, IGHG4 is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in the immune system and its potential applications as a drug and biomarker.

Protein Name: Immunoglobulin Heavy Constant Gamma 4 (G4m Marker)

Functions: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGHG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets